CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Best supportive Care (BSC) + IFX-1Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug340 Best supportive care only Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Pragmatic Adaptive Open Label, Randomized Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

This is a pragmatic, adaptive, open-label, randomized, multicenter phase II/III study consisting of two parts: Phase II and Phase III. In both study parts, patients will be randomized to two treatment arms (Arm A: best supportive care [BSC] + IFX-1; Arm B: BSC alone). After all patients are treated in Phase II, an interim analysis will be performed to assess the clinical benefit of the treatment using the assessed clinical parameters.

NCT04333420 COVID-19 Pneumonia Drug: Best supportive Care (BSC) + IFX-1 Drug: Best supportive care only
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Relative change (%) from baseline in Oxygenation Index (PaO2 / FiO2) to day 5.

Measure: Change in PaO2/FiO2

Time: Baseline to Day 5

Secondary Outcomes

Description: Number of patients (%) achieving an Early Response

Measure: Patients achieving early response

Time: Baseline to Day 7


Related HPO nodes (Using clinical trials)